Related Experiment Video
Updated: Feb 7, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
Left ventricular assist device (LVAD) program in Chile: first successful experience in South America
Oneglio Pedemonte1,2,3, Andres Vera1,2,3, Lorenzo Merello1,2,3
1Department of Cardiovascular Surgery, Hospital Gustavo Fricke, Viña del Mar, Chile.
Insights
Chile
Area of Science:
- Cardiology
- Medical Devices
- Public Health
Background:
- Limited heart transplantation availability necessitates alternative treatments for end-stage heart failure (ES-HF).
- A pilot Left Ventricular Assist Device (LVAD) program was established in a Chilean public hospital to address this need.
Purpose of the Study:
- To evaluate the feasibility and initial outcomes of the first LVAD program in Chile.
- To assess the morbidity and mortality associated with LVAD implantation in ES-HF patients.
Main Methods:
- Retrospective analysis of the first nine patients implanted with LVADs since August 2013.
- Average follow-up of 30 months, detailing key clinical events.
Main Results:
- Nine patients with ES-HF underwent LVAD implantation.
- Survival rates at 6, 12, and 18 months were 89%, 78%, and 78%, respectively.
- One patient received a heart transplant; six remain supported by LVADs.
Conclusions:
- The pioneering LVAD program in Chile is successful, offering a vital alternative for ES-HF patients.
- LVADs provide an effective therapeutic option for patients with donor shortages or contraindications to heart transplantation.
Background:
The need to have a variety of tools to deal with end-stage heart failure (ES-HF), along with the limited heart transplantation availability encouraged us to create a pilot Left ventricular assist device (LVAD) program in a public health care system hospital in Chile.
Methods:
A retrospective analysis of the first nine patients of an ongoing LVAD program initiated on August 2013 was performed, completing an average of 30 months of follow-up. The most important events regarding to morbidity and mortality are described.
Results:
Nine patients with ES-HF underwent LVAD implantation surgery; one of them died 23 days after surgery and another died after 11 months. One patient successfully underwent heart transplantation after 16 months of HeartWare ventricular assist device (HVAD) support; the other six patients remain in the program and have an average follow-up of 846 days at the time of this study (range, 23-1,481 days). The survival rate at 6, 12 and 18 months follow-up was 89%, 78% and 78% respectively.
Conclusions:
This new pioneering LVAD program in Chile has been successful and now constitutes a vital adjunct to all who work in heart transplantation and ES-HF programs. It offers an effective therapeutic alternative when there is a severe donor shortage, in cases of atypical blood types, emergencies, exceptional cases with contraindication for heart transplantation or when there is important donor-receiver size mismatch.
Related Concept Videos
Ecological Succession
What is an Experiment?
Thomson's e/m Experiment
A particle with charge q, speed v, and mass m enters an area from the top, where the magnetic and electric fields are perpendicular both to the particle's motion and to one another. The magnetic...
Controls in Experiments
Randomized Experiments
Simple randomization
Simple...
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.

